Stoke Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $184.4M | $36.6M | $8.8M | $12.4M | — |
| Selling, general & administrative | $67.1M | $48.8M | — | — | — |
| Research and development | $137.9M | $89.1M | $82.2M | $77.8M | $54.2M |
| Operating expenses | $205.0M | $137.9M | $123.6M | $116.8M | $86.1M |
| Operating income | -$20.6M | -$101.4M | -$114.8M | -$104.4M | -$86.1M |
| Interest expense | $9,000 | $26,000 | $49,000 | — | — |
| Income tax expense | $0 | — | — | — | — |
| Net income | -$6.9M | -$89.0M | -$104.7M | -$101.1M | -$85.8M |
| Balance Sheet | |||||
| Cash and equivalents | $84.2M | $128.0M | $191.4M | $113.6M | $144.9M |
| Current assets | $305.7M | $232.8M | $215.3M | $244.1M | $229.2M |
| Total assets | $418.4M | $271.6M | $228.3M | $256.1M | $238.9M |
| Current liabilities | $57.9M | $40.1M | $30.8M | $31.4M | $17.1M |
| Total liabilities | $66.0M | $42.5M | $68.8M | $71.2M | $21.1M |
| Stockholders' equity | $352.5M | $229.0M | $159.6M | $184.8M | $217.8M |
| Cash Flow Statement | |||||
| Cash from operations | $45.6M | -$86.9M | -$81.1M | -$31.9M | -$66.9M |
| Depreciation and amortization | $1.8M | $2.2M | $2.5M | $1.5M | $974,000 |
| Stock-based compensation | $32.2M | $27.5M | $25.3M | $22.9M | $16.4M |
| Capital expenditure | $670,000 | $203,000 | $1.6M | $4.0M | $1.2M |
| Free cash flow | $44.9M | -$87.1M | -$82.7M | -$35.8M | -$68.1M |
| Impairments | $0 | $0 | $0 | $0 | $0 |
Shares outstanding 62.3M · Free float 87.4%
Annual filing data through FY ended December 31, 2025; float as of July 14, 2026.